Source Reference: Limaye AP, et al "Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial" JAMA 2023; DOI: 10.1001 ...

Limaye AP, Budde K, Humar A, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA . Published online ...

Cytomegalovirus is a common virus that is present in many healthy people, rarely causing any problems. However, in kidney transplant patients and others with reduced immune function, CMV infection ...

Cytomegalovirus (CMV) infection is one of the most common complications affecting solid organ transplant recipients.

US FDA approves new indication for Merck’s Prevymis ® (letermovir) for prevention of cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. News release. June 6, 2023.

Both letermovir and valganiclovir, when given for up to 200 days after a kidney transplant, prevented CMV disease for up to 52 weeks at comparable rates of 10.4% and 11.8%.

VANCOUVER, British Columbia—Cytomegalovirus (CMV) infection in kidney or kidney/pancreas transplant recipients occurs more frequently when alemtuzumab is used for induction instead of ...

The incidence of CMV in kidney transplant recipients ranges from 8% to 32%, according to researchers, and it usually occurs in the first 6 months after transplantation.

The FDA recently approved a new indication for Prevymis as a prophylaxis to prevent cytomegalovirus disease in high-risk adult kidney transplant patients receiving organs from CMV-seropositive ...

In a trial, investigators randomly assigned 66 kidney transplant recipients (KTRs) to valA and 71 to valG for CMV prophylaxis after surgery. Of the cohort, 30% were pediatric and 70% adult patients.

The information provided is somewhat limited; however, it seems as though your patient has an active CMV infection. You need to know the limit of detection, or the minimum number of viral copies ...